3 October 2016
HIV Vaccine Trials Network (HVTN) has joined the EURIPRED EXTRANET
The HVTNâ€™s mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV infections globally.
To date, the Network has conducted the majority of the published, presented, or ongoing clinical trials of preventive HIV vaccines worldwide. In the process, we have gained tremendous experience in administering an innovative global scientific organization, which combines the intellectual robustness and creativity of academia with the focus and infrastructure of industry.
One unique advantage of our network experience is that, having done so many studies, we can now look across the results from multiple studies and draw conclusions about vaccine methods and schedules that are worth pursuing versus those that are not as promising. Unlike researchers who work on individual trials, we are able to capitalize on the knowledge gained from every study we undertake. By sharing these data with other researchers in the field, we help the entire HIV prevention effort move forward faster.